Freel Meyers Lab

Johns Hopkins University

PHARMACOLOGY

Baltimore · United States

NIH-funded
Rate this labNo reviews yet — be the first.

Research focus

NIH R01 · 2024

Targeting DXP synthase in bacterial metabolism

There is an urgent need to develop new antimicrobial strategies to combat the increasing occurrence of drug resistance in clinical pathogens. Current antibiotics act on a limited set of cellular processes, and the rate of new inhibitor discovery is rapidly declining. With the diminishing arsenal of useful antibiotics, other essential cellular processes must be explored as antibacterial targets. During infection, bacterial pathogens rapidly respond to changes in the host microenvironment by remodeling metabolism to promote growth. These “metabolic adaptations” are crucial for pathogen survival and pathogenicity in vivo and are thus a promising target space for antibiotic development.…

From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.

Reviews

← All labs at Johns Hopkins University